Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
holy smokes Chester sells this every chance he gets at any price... he must not have any faith in this company.... it's mind boggling how many shares he sells every month
Chad
22 hours ago
From the Yahoo Finance MNTR Conversation Board
Do die diligence
You get some of those MNTR 1.20-130's? You should have done well off those .70's.
This is becoming a bigger ATM with the movement and please tell me you knocked it out of the park these last 2-3 moves. Was the easiest I seen in awhile.
large transactions here, hedge fund buying?
Finally got a red day so you could come out of hiding. So predictable.
LOL, If this stops many are up 300-500% short term. I'd give your boy a big hug and still say thanks for the ride.
Many made 200% in a few weeks here. It will set up shortly again and if news hits this could fly to 5.00 in a blink.
WEED is moving all these plays MNTR included. This was easy to see and play the action. It drops and you buy. When it goes up you sell.
Good grief how much more easier can this get.
It was a question, not an assumption.
Read the post.
Do due diligence.
Irrelevant assumption.
If the SEC stops trading (again), what happens to the stock you would happen to own at that time?
Do due diligence
I did. Great Numbers here and most solid balance sheet the entire sector.very high ROY potential if compare the bubble sector. If any weed comoany need money MNTR is here for you. Heading to 52 wk.high (4.82) for a simple reason. On much better shape a/o today. Good luck w/that strategy.
Research the term: "useful idiots"
Study the history of the "company".
Study the CEO's investment "successes".
Who, besides himself, his latest wife and his pet accountant(s) have made any money from this "company"?
Viewing one or two frames from a long film is a poor investment strategy.
How many people made money when they bought at $8 when this "stock" was pumped before?
Do due diligence
For solid reasons. Every deep is a buy opp. Here since company on much better shape than most sector and MC still 1/10.
Revenues and cash increasing. One of most solid balance sheet ( assets/liabilities ratio=7).
'Cuz only bottom feeders and day-traders "like" $MNTR?
CEO dumping.
No income from MJ.
Consistently loses shareholder's money (though there might be a one-time "profit" from the interest "earned" from Chester's Bhang catastrophe settlement).
Who touts $MNTR as a long-term investment?
Do due diligence
Surprised how quiet the board is. $MNTR
Headed back to HOD now it seems. $MNTR
Expecting a great month. Link back.
With MNTR up big past few weeks, seems many have disappeared with the great fortune or are waiting for another nice pullback.
MNTR is a great ATM and many have made some serious coin here and will continue.
almost took this one off the shelf and did the tax loss thing...damn glad i didn't! Looking realllly good now....
Hope you held and are now are plus BIGTIME!!
Warming up towards January: California Goes Marijuana Crazy on Jan. 1 https://twitter.com/ash_trader/status/946683658781552641
Looks like everyone is making some serious MNTR money here. Hope you held and are now are plus BIGTIME!!
MNTR should get interesting with CA. legal.
And nice way to end the year with 2 mill payoff.
Uptrend for solid reasons. Company on much better shape a/o today ( revenues, cash and the solid balance sheet) relating a year ago ( 52 wk.high $4.82).
Load the boat! She's ready for another leg up! $MNTR
interesting. agree. Mentor Capital,the bullish pattern is re-confirmed for solid reasons, beside most solid balance sheet among the entire sector, receiving $2m in cash. she might check 52 wk. high the near future imo. cap is pretty low and the company currently generating revenues (increasing ) and the balance sheet very solid and i have been researched a lot of cannabis companies, most sector trading $100m to $200m ( no revenues, bad balance sheets including negative Equity). assets/liabilities ratio=7, that's pretty rare solid ratio. none even gettin close to it.
Cograts, we headed to 2.00? Amazing stock all.
ATM here and enjoy the spoils.
SIGO chart is setting up for a major breakout. Major buy signal about to hit which will be picked up on all scanners. Perfect combo storm about to hit with MJ mania starting next week. People home for the holidays will all be spreading the word to buy MJ stocks as January is ground zero for Cali blast off. Cheech and Chong up in smoke about to come to fruition!
SIGO: super low float, no toxic debt, operational, laboratory certs, fully licensed with more license approval on the way.
Buy now, thank me later
At least Chester spelled "Mentor Capital" correctly on this card, something he has not done in previous years
mentor xmas card $2 milly gift
$2+ million Paid to Court by Bhang
Seems odd that only the "insiders" Chester shares with know Bhang has placed $2,040,000.00 with the court to satisfy the judgement. It is easily found in the Federal court information about the case. Guess that is the "big" news he has been telling people about.
Wouldn't everyone consider that relevant information??
I am here to trade not make a life long investment. You have been here so long that now you refer to the CEO as "aging" lol
You should meet aging $MNTR CEO Chester Billingsley
That would be doing due diligence
Doing so might influence your decisions
Doing due diligence is a good thing
Ummm yes. That is why all are here. Maybe figure that out earlier and make some serious MNTR change.
I have never seen anyone hate a stock and its ceo so much for so long. This stock is a virtual atm.
All waiting for the pullback to .70-.80's.
Be ready as MNTR is a ATM for the past few years.
MJ companies making this a real player. Enjoy the ride up again.
Up another 40%. Sad you left as many doubled and tripled in less than a Month.
MNTR is the ATM and you lost the address.
Aging $MNTR CEO Chester Billingsley: Why I'm selling
From a post by "Vern" from the Yahoo Finance website:
Vern
8 months ago
My communication between Chet Billingsley
So initially sent their Contact Us link an email asking them to to ask their CEO to stop dumping stock and showing weakness in the company. I received the following response....
Dumb CEO here. I obviously need some help and your suggestions are appreciated. I apparently made a mistake and I am thinking out loud with you. For 20 years I have paid myself $104,000 per year (vs $250,000 to $450,000) for other public company CEO’s. I did not issue myself stock options nor shares. I didn’t sell any shares for the preceding 15 years or so before August 2016. I only rewarded myself by increasing the market cap of MNTR from $260,000 to $45,000,000 over a 17 year period. 100% of my family’s net worth was happily tied up in the business of MNTR which was my “bank” storing my families wealth. With two boys in out of state schools and significant medical issues in the family I just had to earn more than $1,300 net per week. So, I researched it and saw that under SEC safe harbor of a 10b5-1 plan I could sell about 5,000 shares each of three days per week out of my 5,000,000 shares. When I started this in August the share price was 30 cents. Now the share price is $2.07/sh. I felt if I was trickling in 15,000 shares per week into the market, that would not interfere with share price growth, which it did not for the 600% growth that following my start of leaking in shares on a level basis.
However, the SEC asks for notice within 48hrs in a Form 4 even if I sell 200 shares. So, you see 6 to 10 share Form 4 sale reports each month even though I am trickling in only a fraction of the ongoing share volume. This looks bad. But, in theory, selling small amounts spread over time is as gentle as possible on the share price. In theory I’m doing what is best, but in practice I do nothing but irritate the heck out of you. I’ll work on it. Thanks for the nudge.
Best in All Things,
Chet Billingsley, Chairman & CEO
? M E N T O R C A P I T A L , I N C. (MNTR)
Post Office Box 1709 ? Ramona, CA 92065
Dir: (760) 788 - 4700 ? Fax: (760) 788 - 2525
MNTR was being pumped by a few scumbags trying to steal people’s money. I hope it continues to go up, but the pump and soon dump will probably happen.
Followers
|
131
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3662
|
Created
|
02/15/10
|
Type
|
Free
|
Moderators |
Authorized Shares 75,000,000 02/05/2021 Outstanding Shares 22,730,793 02/05/2021 Float 19,883,188 11/04/2020 |
| | |
VIDEOSCannabis: Harvesting the 600% Growth, Without Taking a Hit |
Management Today Magazine: ![]() Click to Read Full Article Portfolio & Investments |
Metro Capital, Inc. (MNTR) is a public company that invests in medical and social use cannabis companies. Mentor takes a 10% to 60% position in the family of participating companies, but leaves operating control firmly in the hands of the cannabis company founders. Because adult social use and medical marijuana opportunities often overlap, Mentor Capital also participates in the legal recreational marijuana market. However, Mentor’s preferred focus is medical, and the company seeks to facilitate the application of cannabis to cancer wasting, calming seizures and Parkinson disease, reducing ocular pressures from glaucoma, and blunting chronic pain.
Mentor’s approach and capital structure allows its shareholders to buy an additional $140 million of Mentor shares at approximately a 12.5% discount. As money is sent in to buy into the growing cannabis portfolio, the proceeds are split pro rata amongst the cannabis companies that are participating in the indirect sale in order to receive funding. As more private cannabis companies join in the consortium, the higher the MNTR share price is pushed, other things being equal. The increasing share price increases the exercise of stock options and warrants by both Mentor Capital’s 1,500 mostly accredited shareholders and the public market in general. Using this approach, Mentor can deliver a higher price to founders for a smaller slice of their business. Retaining control and receiving more cash are the two key advantages to cannabis founders working with Mentor Capital, Inc.
Only 3% of the illegal marijuana market has, at the beginning of 2014, been shifted into the legal sector. This implies a 30x potential increase in the size of the cannabis market upon the eventual realization of a federal lifting of the prohibition on cannabis, if lifted for both medical and adult social use. The 30x implied illegal to legal potential market shift may be one factor in why the market capitalization sof some public cannabis companies are in the 30x revenue (i.e. sales) range. The $1.4 Billion legal cannabis market is forecast to grow by 63% during 2014. It is important to note that this 63% annual increase in sales or even the entire 30x potential increase requires no true growth in the overall cannabis market or other growth in cannabis usage. The modeled growth is satisfied, in our understanding, by the shifting of cannabis buyers to legal sellers rather than them risking buying through any remaining illegal channels. The $50 Billion market already exists and does not need to be developed, just shifted over. Antidotal evidence in Denver indicates that illegal channels are already expressing resentment toward the decline in street sales because of the shift to legal, controlled cannabis sale.
To lead and capture a major portion of the potential 30 times increase in the legal cannabis market Mentor Capital's investing strategy is:
1) Be first with significant public money
2) Quickly roll up the best cannabis participants in a public vehicle
3) Bring a high level of character and business professionalism to the marijuana investing sector
Mentor is authorized (almost like a group IPO) to raise $140 million from the public market and is committing those funds to the cannabis companies that join in the cooperative portfolio, trading a slice (10% to 60%) of their business in exchange for public market funding. To Mentor's knowledge, Mentor Capital is the first public company to commit this level of a cash raise to the cannabis market.
In any very rapidly growing situation, companies need large amounts of capital to keep pace with the growth opportunity. It is hoped that the cannabis firms Mentor funds will have a significant advantage in absorbing a large share of the expected business expansion.
In order to apply the $140 million fully and quickly, Mentor Capital has been very aggressive in recruiting cannabis companies to secure their share of a funding portfolio. A very high price in future proceeds is offered, against the backstop of starting within a $1.4 Billion legal market and looking to expand to encompass the $50 billion already existing illegal market, all implying a 30x market growth.
The current public market multipliers are in the 30x to 80x revenues range. This, quite possibly because there is a projected near term market growth of 30 times. Almost any reasonably solid, well-financed company will do well in this sort of environment. Mentor is quite experienced in picking solid companies and even very high offers will still be much less than 30x revenues. This all gives encouragement to green light a roll up of the best available cannabis companies in each sector and region. This investment and acquisition approach may have an expectedly high return but surprisingly low business risk, in our examination.
A final plank in the Mentor Capital investment strategy is qualitative and is pushing to bring a high degree of business professionalism and transactional integrity to the marijuana public market. As a first, the CEO voluntarily placed all of his MNTR shares in escrow with a law firm. This, to address the widespread concerns that pump and dump schemes are prevalent in the medical marijuana market. Additionally, the CEO is taking the role of the non-user, designated driver in this cannabis industry involvement. Finally, following from the West Point, Harvard, General Electric formal approach to the world, all interactions are structured to be 100% business and win-win-win. In an open way all business transactions should be a win for Mentor, for cannabis founders, and the investing public.
This formal, win-win-win, all business approach is a natural one for Mentor Capital. Management hopes in this way to attract the cannabis founders of the best cannabis brands. These founders are brought together with conservative investors who are still looking for a solid business approach within this extraordinary opportunity.
Chester Billingsley is a native of Minnesota, born in 1952. He received a congressional appointment and did his undergraduate work at West Point. Later he went to graduate school at Harvard University where he received a Master’s Degree in Applied Physics with concurrent study at Harvard Business School and at MIT studying proton radiology as applied to difficult to treat cancers, in conjunction with Mass General Hospital.
Mr. Billingsley spent the major portion of his early career at General Electric in technical sectors in project, turn-around and international management positions. In 1985 he formed Tech Start, the predecessor to Mentor Capital in the heart of Silicon Valley. He has held the general manager or president position since that time.
In 1995 he took the firm public and has had lead responsibility in the Tech III Partners, Cambridge Equity Partners, and Mentor Investors I, LP financial partnerships. He has directed the successful acquisition or investment in thirty-six operating business or entities.
Mr. Billingsley is a conservative, 61 years old, non-using businessman. In August 2013, he led the surprising but science-based decision to take Mentor Capital into the medical marijuana space. The goal was to pursue an alternative approach to fighting cancer while seeing significant shareholder returns.
As a public company pioneer in the legal cannabis space, Mr. Billingsley became a founding director and officer of the board of directors of the Nevada Cannabis Industry Association in November 2013.
Market Value1 | $12,196,693 | Jan 17, 2014 |
Shares Outstanding | 6,419,312 | Sep 30, 2013 |
Float | 1,545,670 | Sep 30, 2011 |
Authorized Shares | 400,000,000 | Sep 30, 2013 |
Shareholders of Record | 1,561 | a/o Sep 30, 2011 |
Mentor Capital (MNTR) Invests in Leading-Edge Cancer Therapy & Drug Development Companies
Filings
http://www.otcmarkets.com/stock/MNTR/filings
Summary Data. Management Team. Professional Support. Philosophy.
Ethics. Corporate Governance.
http://www.mentorcapital.com/About-Mentor-Capital.html
Portfolio Companies
Advaxis, Inc. (ADXS)
Advaxis is a biotechnology company that uses a harmless bioengineered bacterium, Listeria monocytogenes to activate the immune system to treat cancer. A vaccine of incapacitated bacteria infiltrate cancer cells. The body attacks the cells containing or marked by the bacteria, killing the cancer cells.
Antigenics (AGEN)
Biotechnology company developing cancer vaccines and other treatments for cancer and infectious diseases.
BioVest International, Inc. (BVTI)
Biovest International develops personalized immunotherapies for life threatening cancers of the blood system.
Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases.
CEL-SCI (CVM)
CEL-SCI is dedicated to improving the treatment of cancer and other diseases by unleashing the power of the immune system; the body's natural and most potent defense system.
Dendreon (DNDN)
To target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.
Generex Biotechnology Corporation (GNBT)
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).
Hadron Systems, Inc. (Private)
Widely recognized by cancer immunologists is the communicative role of tumor stromal cells that shield tumors from the immune system, and the potential of vaccines with inhibiting properties. Hadron Systems, Inc. - a privately held company - represents the targeting and ablation of tumor stroma via targeting/nucleus internalization in combination with particle therapy (the product). The product is classified as a medical device, and a clinical trial to include late-stage cancer patients is planned for September 2012.
ImmunoCellular Therapeutics, Ltd. (IMUC)
ImmunoCellular Therapeutics, Ltd. (OTC:IMUC.OB) We are a clinical-stage company that is focused on developing new therapeutics to fight cancer using the immune system. Our product pipeline includes peptide based vaccine to target cancer stem cells, cellular immunotherapies to target cancer associated antigens, and monoclonal antibodies to diagnose and treat several different cancers. Our main disease focus using our immunotherapy technologies is to treat glioblastoma, but these therapies may also be applicable to multiple other cancers such as pancreatic, colon and breast cancers due to presence of similar epitopes on these malignant cells. Our antibodies are designed to treat small cell lung cancer, pancreatic cancer, multiple myeloma and ovarian cancer.
Northwest Biotherapeutics, Inc. (NWBO)
Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer.
Oncothyreon (ONTY)
Oncothyreon is a biotechnology company dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients.
Provectus Pharmaceuticals, Inc. (PVCT)
Provectus Pharmaceuticals, Inc., with its home office in Knoxville, Tennessee, is developing advanced prescription drugs in the fields of oncology and dermatology. Clinical trials of our cancer drug PV-10 for the treatment of melanoma, breast cancer, and liver cancer are currently being conducted. PH-10, our topical formulation of Rose Bengal, is also in clinical trials for psoriasis, atopic dermatitis, and eczema.
MNTR's objective is to help defeat cancer by funding $125 Million into the best new cancer fighting companies. MNTR equity is targeted to the critical gap between non-profit discovery and Big-Pharma sales.
To inject funds into the cancer companies (rather than trade in the market) MNTR seeks to directly acquire and escrow $125 Million in shares from fifteen Cancer Index or other leading firms. Any resulting net exercise in MNTR's $125 Million in freely tradable warrants are paid out pro rata to the cancer fighters under MNTR's standard Long-Term Equity Funding Contract.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |